Avrion Therapeutics was founded in 2020 based on more than 10 years of research at EPFL. Avrion’s mission is to develop its first product AVR-001 as a treatment for amyotrophic lateral sclerosis (ALS) in addition to other programs of precision gene therapy solutions for neurodegenerative diseases.
Products, services, technology
Avrion’s gene therapy technology uses vectors to deliver therapeutic gene sequences to discrete cell types in the central nervous system. Avrion's first clinical candidate, AVR-001, is preparing to enter IND-enabling studies to treat patients with amyotrophic lateral sclerosis - ALS.